MarketPulse

public offering

88 articles
BenzingaBenzinga··Na

Revolution Medicines Raises $2.2B in Upsized Offerings to Fuel R&D Pipeline

Revolution Medicines closes $2.2B concurrent offerings, including equity and convertible notes, to accelerate drug development and commercialization.
RVMDRVMDWclinical developmentpublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Trevi Therapeutics Raises $150M to Advance Nalbuphine Program for Chronic Cough

Trevi Therapeutics prices $150M stock offering at $13/share, raising capital for Haduvio development across chronic cough indications.
TRVIclinical-stagepublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

York Water Taps Capital Markets With Stock Offering to Fund Growth Strategy

York Water Company announced a proposed public stock offering on April 15, 2026, with proceeds earmarked for capital investment, debt reduction, and potential acquisitions.
YORWacquisitionsdebt repayment
BenzingaBenzinga··Not Specified

Army Taps Powerus Drone for Historic Ranger Competition as SPAC Merger Advances

Powerus' Matrix-T drone selected for U.S. Army Best Ranger Competition. Company merging with AGH to go public as PUSA on Nasdaq by summer 2026.
AGHmergerpublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Revolution Medicines Raises $2B in Upsized Stock and Convertible Offerings

Revolution Medicines raises $2.0 billion via 10.56M shares at $142/share and $500M convertible notes for R&D and commercialization.
RVMDRVMDWclinical developmentpublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Spyre Therapeutics Prices $403M Stock Offering at $62 Per Share

Spyre Therapeutics prices $403M stock offering at $62/share with 6.5M shares, expected to close April 16, 2026. Prominent underwriters include Goldman Sachs and Jefferies.
SYREpublic offeringcapital raise
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Allogene Therapeutics Raises $175M Via Stock Offering to Fund Clinical Pipeline

Allogene prices 87.5M shares at $2.00 each, raising $175M gross proceeds for clinical trials and R&D operations.
ALLOclinical trialspublic offering
BenzingaBenzinga··Globe Newswire

Spyre Therapeutics Raises $300M in IPO as IBD-Focused Biotech Advances Pipeline

Clinical-stage biotech Spyre Therapeutics launches $300M public offering to fund inflammatory bowel disease drug development, with major investment banks leading.
SYREpublic offeringcapital raise
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Spyre Therapeutics Raises $300M in IPO to Fund IBD Drug Development

Clinical-stage biotech Spyre Therapeutics announced $300M public offering with $45M underwriter option, led by Jefferies and Goldman Sachs, targeting IBD treatments.
SYREpublic offeringcapital raise
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Malaysian Wire Harness Maker Linkers Industries Fully Exercises Warrants Post-Reverse Split

$LNKS completes full exercise of Series B warrants using zero-price option following 250-for-1 reverse split, restructuring capital base.
LNKSwarrant exercisepublic offering
BenzingaBenzinga··Na

NUAI Launches Public Stock Offering to Refinance SharonAI Debt

New Era Energy & Digital announces underwritten public offering to repay convertible note to SharonAI, with Northland Capital Markets as lead manager.
NUAINUAIWSHAZdebt repaymentpublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Celldex Therapeutics, Inc.

Celldex Raises $345M in Public Offering as Underwriters Exercise Full Option

Celldex Therapeutics closed $345M public offering at $29/share with full underwriter option exercise, netting approximately $401M in total gross proceeds.
CLDXpublic offeringcommon stock
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Celldex Raises $300M to Fuel Barzolvolimab Launch and Pipeline Expansion

Celldex prices $300M stock offering at $29/share to fund commercial launch of CSU treatment and expand bispecific antibody platform.
CLDXbarzolvolimabclinical development
GlobeNewswire Inc.GlobeNewswire Inc.··Fibrobiologics, Inc.

FibroBiologics Prices $3M Offering, Advances Diabetic Ulcer Drug

FibroBiologics prices $3M offering and validates manufacturing of CYWC628 for diabetic ulcer trials while restoring Nasdaq compliance.
FBLGclinical trialpublic offering
BenzingaBenzinga··Tanya Rawat

Datacentrex Stock Plummets 25% After Hours on $20M Dilutive Offering

Datacentrex ($DTCX) shares crashed 25.57% after-hours following announcement of $20.17M public offering at $2.00 per share, well below recent trading levels.
DTCXpublic offeringafter-hours trading
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Zenas BioPharma Raises $300M Through Convertible Notes and Stock Offering

Zenas BioPharma prices $300M offering combining $200M convertible notes and 5M common shares to fund obexelimab launch and pipeline advancement.
ZBIOautoimmune diseasesequity offering
BenzingaBenzinga··Globe Newswire

Datacentrex Prices $20.17M Share Offering at $2.00 Per Share

Datacentrex prices confidential offering of 10.085M shares at $2.00 each, raising $20.17M for working capital and corporate purposes.
DTCXequity offeringpublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Datacentrex Raises $20.17M via CMPO at $2.00 Share Price

Datacentrex prices $20.17M offering at $2.00 per share, closing March 30, 2026. Proceeds support working capital and general corporate needs.
DTCXequity offeringpublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Rogers Communications Raises $2.5B via Subordinated Notes to Refinance Debt

Rogers Communications prices $2.5B dual-currency subordinated notes offering, with proceeds directed toward debt refinancing through 2056 maturity.
RCIprivate placementdebt repayment
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Apogee Therapeutics Raises $350M via Public Offering to Fuel Biotech Pipeline

Apogee Therapeutics prices $350M offering at $70/share to fund development of inflammatory disease treatments, with lead candidate Zumilokibart targeting atopic dermatitis.
APGEclinical-stagepublic offering